Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

New inhibitors are urgently needed to overcome the burgeoning problem of drug resistance in the treatment of Plasmodium falciparum infection. Targeting the folate pathway has proved to be a powerful strategy for drug development against rapidly multiplying systems such as cancer cells and microorganisms. Antifolates have long been used for malaria treatment but, despite their success, much less is known about parasite folate metabolism than about that of the human host. In this article, we focus on folate enzymes used clinically as anticancer drug targets, in addition to those that have potential to be used as drug targets, for which there are inhibitors at various stages of development. We discuss how this information could lead to the identification of new targets in malaria parasites.

Original publication

DOI

10.1016/j.pt.2005.04.002

Type

Journal article

Journal

Trends Parasitol

Publication Date

06/2005

Volume

21

Pages

292 - 298

Keywords

Animals, Antimalarials, Drug Resistance, Folic Acid, Folic Acid Antagonists, Humans, Malaria, Falciparum, Multienzyme Complexes, Plasmodium falciparum